Normal antibody response after COVID-19 during treatment with cladribine

Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies thr...

Descripción completa

Detalles Bibliográficos
Autor principal: Celius, Elisabeth G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832623/
https://www.ncbi.nlm.nih.gov/pubmed/32882501
http://dx.doi.org/10.1016/j.msard.2020.102476
Descripción
Sumario:Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.

Ejemplares similares